PharmacoPhotonics Inc. raised $1.5 million in equity to develop a device that measures kidney function.
The company’s device can provide a measure of the kidney’s function, or glomerular filtration rate, in 15 to 30 minutes. Current methods of determing GFR either provide a rough estimate or require collecting a patient’s urine samples over a 24-hour period.
The Indianapolis-based company is a spinoff of Indiana University’s Center for Biological Microscopy and was incorporated in 2006.
“There is a big clinical need for this in the hospital,” Center Director Dr. Bruce Molitoris said in a press release. “We can’t tell the kidney function of a patient during acute kidney injury in a rapid fashion that would allow us to make diagnostic and therapeutic decisions.”
The fund-raise comes from 20 investors, with a $5,000 minimum investment amount, according to a regulatory filing. PharmacoPhotonics received the funding commitments over the last year, with the first sale occurring in June 2009.
CEO Joe Muldoon did not immediately return a call.
At DeviceTalks Boston, Tyler Shultz will give attendees an inside look at Theranos and how he was able to sound the alarm after he realized the company was falling apart. Shultz will take attendees behind the story that everyone is talking about: the rise and fall of Elizabeth Holmes and her diagnostic company, Theranos.
Join Shultz and 1,000+ medical device professionals at the 8th annual DeviceTalks Boston.